Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierre, Samuel, Bocharova, Iryna, Nguyen, Catherine, Homeus, Fabienne, Julmiste, Gaetane, Macius, Youry, Rouzier, Vanessa, Severe, Patrice, Marcelle Deschamps, Marie, Moise, Colette Guiteau, Bellot, Clovy, Wu, Johnny, Rivera, Vanessa R, Sun, Rochelle, Pape, Jean W, Liautaud, Bernard, Koenig, Serena P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661077/
https://www.ncbi.nlm.nih.gov/pubmed/34901303
http://dx.doi.org/10.1093/ofid/ofab559
Descripción
Sumario:We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

Ejemplares similares